Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Inflarx n.v. save search
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: -7.89%
covid-19 application update study
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
Published: 2022-12-21 (Crawled : 13:20) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 10.9%
H: 17.09%
C: 15.38%
covid-19 treatment agreement china
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: -4.4%
H: 4.21%
C: 2.68%
inf904 c5ar study
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
Published: 2022-07-26 (Crawled : 12:20) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 6.47%
H: 44.59%
C: 29.73%
covid-19 treatment fda authorization emergency use authorization
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
Published: 2022-03-17 (Crawled : 12:00) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 2.29%
H: 16.59%
C: 10.31%
fda program
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
Published: 2022-03-08 (Crawled : 13:30) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: -8.33%
H: 4.55%
C: 0.45%
ces derm trial presentation
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
Published: 2022-01-05 (Crawled : 17:00) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 3.21%
H: 10.89%
C: -6.0%
health ces thc conference presentation j.p. morgan healthcare conference
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
Published: 2021-11-03 (Crawled : 12:15) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 5.38%
H: 2.43%
C: -0.41%
conference
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.